• CSL Limited retains rights to clazakizumab in end-stage kidney disease. • Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in competition with Novo Nordisk and Novartis. • The post Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug appeared first on MedCity News .
Article Summaries:
- Eli Lilly has agreed to pay $100 million to CSL Limited for the rights to clazakizumab, an interleukin‑6 (IL‑6) blocking antibody. CSL will keep its exclusive rights to the drug for end‑stage kidney disease, while Lilly will obtain the rights for all other indications. The acquisition positions Lilly to compete with major players such as Novo Nordisk and Novartis in the broader inflammation‑targeted therapy market. The deal underscores the growing interest in IL‑6 inhibitors for treating a range of inflammatory conditions beyond kidney disease.
Sources: